Recce Pharmaceuticals Announces Multiple Patients Dosed with RECCE® 327 in Topical Phase I/II Clinical Trial for the Treatment of Infected Burn Wounds

Joey Cohen
Medication Adherence

Brenda Snow
Authentic Patient Voice

Liz Kane
Impactful Strategy

Matt Turner
Patient Affordability

Matthew Durham
Omnidynamic Marketing

Stacey Gandler
Brand Nourishment

Suma Ramadas, PhD
Medical Affairs

David Linetsky
Point-of-Care Marketing

Frank Burrell
Scientific Storytelling

Paul Theisen
Patient Acquisition

Amy Giles
Increasing Engagement

Bud Bilanich
Success Coach

Daniel Sontupe
Market Access

Pat Purcell
Meeting Engagement